May 25, 2012 - We are pleased to announce that Sanovas has been chosen by Frost & Sullivan as the recipient of its prestigious "2012 North American Medical Device New Product Innovation Award in Pulmonary Disease."

In advance of the "official" announcement, expected in the days ahead, we wanted to share this exciting news for Sanovas and the millions afflicted with lung cancer and chronic pulmonary disease.

Notably, Sanovas is the first Pulmonary Disease Company to be recognized by Frost & Sullivan for contributions in the area of respiratory disease. We believe this recognition is a great validation of the revolutionary advances Sanovas is making in the Interventional Sciences.

We believe this award is a testament to the importance of finding new treatments in the face of the urgent humanitarian and economic impact pulmonary disease is having on families and communities worldwide.

In considering candidates for this award, Frost & Sullivan, a highly regarded global market research and consulting firm, took into account innovation of product, use of leading-edge technologies, value-added benefits and features, and customer acquisition and penetration potential. Here are a few snippets of what Frost & Sullivan analysts had to say about Sanovas' technology:
"The Vas Zeppelin catheter-based microsurgery system developed by Sanovas is a feat in medical device convergence, unlike any other innovation. Typically when talking about a convergent medical device, companies imply the product is a two in one drug-device combination, diagnostic-treatment tool, or imaging-intervention product of some variety. However, Sanovas has developed an all in one device that can provide real-time imaging, access, resection, diagnostics, and drug delivery functionality in one system."

"...the treatment approaches and outcomes for addressing lung cancer have not advanced significantly in the last 20 years, especially when compared to other forms of cancer like breast and prostate. Frost & Sullivan believes the Vas Zeppelin system could be the breakthrough that significantly alters that paradigm. Early detection and intervention could be the key to providing patients diagnosed with lung cancer a more optimistic prognosis."

"Sanovas Inc's innovative Vas Zeppelin system represents a major leap forward in the tools available to address lung cancer and other airway obstructions. Its unique multi-functional combination device draws from a comprehensive vision of disease diagnosis and treatment. The Sanovas engineering team in its specific design nuances demonstrates a keen understanding of the unique set of requirements and features that could greatly impact the outcomes of surgical planning and execution."

About Frost and Sullivan: Frost & Sullivan, founded in 1961, has more than 40 global offices with more than 1,800 industry consultants, market research analysts, technology analysts, and economists. Their mission is to research and analyze new market opportunities for corporate growth. They are the world leader in growth consulting and the integrated areas of technology research, market research, economic research, corporate best practices, training, customer research, competitive intelligence, and corporate strategy.

FDA REGULATORY DISCLOSURE: Sanovas Inc. is an emerging technology company.
These products are investigational medical devices that have not been approved or cleared for use in the United States.